Maryland Cannabis Business Valuation & M&A Advisory: Enterprise Equity

Valuation begins with purpose, because the standard of value and the resulting conclusion differ depending on why the number is needed. A negotiated sale between unrelated parties, a buyout of a departing owner under an operating agreement, an estate or gift transfer, a lender's collateral assessment, and a litigation matter can each produce different defensible figures for the same business. We fix the standard of value, the premise of value, and the valuation date at the outset and state them explicitly in the analysis.

The asset-based approach values the enterprise as the sum of its assets less liabilities, with each asset adjusted from book to fair value. For a Maryland cannabis operator that means restating inventory to a realistic net realizable value rather than a carrying amount inflated by capitalized cost, appraising cultivation and extraction equipment on a used-market basis where the buyer pool is genuinely narrow, valuing leasehold improvements at the value they carry to a buyer rather than at their construction cost, and separately valuing the license itself. Asset-based conclusions typically establish a floor and are most relevant for underperforming operators or where the license is the primary asset being acquired.

The market-based approach applies multiples derived from comparable transactions. In cannabis this requires care: publicly reported multiples frequently come from multi-state operators in mature markets with capital structures and scale that a single-site Maryland licensee does not share, and headline figures often omit earnouts, assumed liabilities, and non-cash consideration. We adjust for market maturity, license scarcity in the specific Maryland jurisdiction, vertical integration, remaining lease term, and the composition of consideration, and we disclose the adjustments rather than burying them in a selected multiple.

The income approach is applied where earnings are sufficiently stable to support it, discounting projected cash flows at a rate that reflects the sector's genuine risk profile: regulatory change, tax regime transition, banking constraints, price compression as license counts expand, and key-person dependence. Two adjustments dominate the cannabis income model. First, normalized earnings must reflect the actual tax burden under the applicable regime, and where a rescheduling transition changes that burden, the model must show both states rather than assuming the favorable one. Second, working capital requirements in cannabis are heavier than general benchmarks suggest, because inventory cycles are long and tax remittances are large.

We weight the approaches according to the facts and explain the weighting. A conclusion presented as a single number without the reasoning behind the weighting is not usable in a negotiation, a filing, or a dispute.

Most Maryland cannabis transactions are structured as asset purchases rather than equity purchases, because a buyer generally prefers to acquire defined assets without inheriting unknown liabilities — and in cannabis the unknown liabilities can include unremitted trust taxes, unresolved 280E positions from open years, employment claims, and regulatory violations. The structure decision is made jointly with counsel and tax, because the regulatory pathway sometimes favors the opposite conclusion.

Purchase price allocation across acquired assets drives the buyer's future depreciation and amortization and the seller's character of gain, and it must be consistent between the parties. We prepare the allocation schedule with support: tangible assets by category, inventory at a valuation the buyer can actually carry, identifiable intangibles including the license interest, brand, customer lists where permitted, and non-competition covenants, with residual goodwill. Allocating aggressively toward rapidly recoverable categories without support creates an exposure that surfaces years later on both sides.

Because a Maryland license cannot simply be handed over at closing, transactions are typically structured with a signing-to-closing period conditioned on regulatory approval. The agreement must address who operates and who bears economic risk during that interval, how inventory and cash are counted and settled at closing, what happens if approval is delayed or denied, and how the purchase price adjusts for changes in working capital between signing and closing. Interim operating covenants matter here: a buyer needs assurance the business will not be run down while approval is pending.

Escrow and holdback provisions carry unusual weight in cannabis. We advise sizing escrow against the specific quantified risks that diligence identifies — open tax years, inventory valuation uncertainty, Metrc reconciliation gaps, license condition compliance — rather than applying a generic percentage. Earnouts are modeled with explicit definitions of the measurement metric, the accounting policies used to compute it, and the buyer's operating covenants during the earnout period, because an earnout on a metric the seller no longer controls is a dispute waiting to be filed.

On the sell side we run pre-transaction preparation: clean the financial records, complete outstanding reconciliations, document the cost accounting methodology, resolve known compliance findings, organize license and contract documentation, and prepare a quality-of-earnings-ready adjustment schedule. Buyers price uncertainty. Removing uncertainty before the process starts is the highest-return work a seller can do.

The Maryland Cannabis Administration regulates who may hold an ownership or control interest in a licensed entity, and transfers of ownership require disclosure and approval. The financial structure and the regulatory filing must describe the same transaction, in the same terms, with the same numbers. Where they diverge — because a financing arrangement confers economic control that the ownership schedule does not reflect, or because a management agreement functions as a de facto transfer — the resulting problem is a licensing problem, and licensing problems put the entire asset at risk.

We prepare the financial side of the disclosure package: capitalization tables before and after the transaction, identification of direct and indirect ownership interests through intervening entities, source-of-funds documentation for each contributing party, disclosure of debt instruments with conversion or participation features that affect economic ownership, and the management and services agreements that bear on control. Beneficial ownership is traced through the full chain rather than stated at the first tier.

Timing is planned backward from the approval requirement. Regulatory review takes time, and transaction agreements must accommodate it without leaving either party exposed. We build the closing timeline around realistic review periods, define what occurs if approval is delayed, and coordinate the sequence of filings so that the operating business continues without interruption to its licenses, its banking, its vendor relationships, or its Metrc continuity.

Post-closing, the financial records must reflect the new structure cleanly from day one: opening balance sheet with the purchase accounting applied, revised chart of accounts if the acquirer's reporting standard differs, transition of the Metrc reconciliation process without a gap, and a documented handover of the cost accounting methodology so the buyer's future positions rest on the same foundation the diligence relied on. We frequently stay engaged through the first several closes after a transaction for precisely that reason.